Nt-probnp

Nt-probnp

Clinical Applications of Immunoassays

Published in Richard O’Kennedy, Caroline Murphy, Immunoassays, 2017

N-terminal pro-BNP (NT-proBNP), another cleavage product from the prohormone pro-BNP, can also be used in diagnosing heart failure. Of note, NT-proBNP is secreted in left ventricular heart failure in higher concentrations when compared to plasma BNP [29]. In immunoassays, a NT-proBNP level >900 pg L−1 has similar accuracy to the plasma BNP level of >100 ng L−1; however, higher levels are detected in women, older individuals and those with renal failure.

A profile on the CardioMEMS HF system in the management of patients with early stages of heart failure: an update

View Article

Journal Information

Published in Expert Review of Medical Devices, 2023

Rohit Vyas, Mitra Patel, Samer J. Khouri, George V. Moukarbel

More recently, two additional studies have provided further evidence for the utilization of the CardioMEMS HF system in patients with HF. The GUIDE-HF study was a multi-center, randomized study which compared HF management guided by PA pressure obtained remotely via CardioMEMS to standard-of-care HF management using guideline directed medical therapy (GDMT) [15]. This study enrolled NYHA II-IV HF patients regardless of left ventricular ejection fraction who had a heart failure hospitalization within the 12 months prior to study consent or elevated natriuretic peptide (BNP or NT-proBNP) levels within 30 days prior to study consent. One thousand patients were randomly assigned to treatment (n = 497) or control (n = 503) groups. Patients likely to receive a heart transplant in the next 12 months or those who had required inotropic support in the previous 6 months were excluded.

Explore chapters and articles related to this topic

Clinical Applications of Immunoassays

A profile on the CardioMEMS HF system in the management of patients with early stages of heart failure: an update